

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SECRETARY OF THE SENATE

03 AUG -7 AM 11:01

**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) -All Filers Are Required to Complete This Page

1. Registrant Name <b>Bristol-Myers Squibb Company</b>			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address <b>655 15th St., NW</b> City <b>Washington, DC</b> State/Zip (or Country) <b>20005 USA</b>			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name <b>Richard Thompson</b>		Telephone <b>(202) 783-0900</b>	E-mail (optional) _____
7. Client Name <input checked="" type="checkbox"/> Self			5. Senate ID # <b>7053-12</b> 6. House ID # <b>7053</b>

**TYPE OF REPORT** 8. Year 2003 Midyear (January 1-June 30)  OR Year End (July 1-De

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  >> Termination Date \_\_\_\_\_

11. No Lobby

**INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

12. Lobbying Firms	13. Organizations
<b>INCOME</b> relating to lobbying activities for this reporting period was:	<b>EXPENSES</b> relating to lobbying activities for this rep period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)	\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u><b>\$2,580,000.00</b></u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of
	<input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definit
	<input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 603: the Internal Revenue Code
	<input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162: Internal Revenue Code

Signature  Date 8/1/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs Page

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ADV (one per page)

16. Specific Lobbying issues

**H.R.149 , Say No to Drug Ads Act, Lobbied to ensure that any restrictions did not inadvertently impede the access to accurate information about pharmaceutical products.**

17. House(s) of Congress and Federal agencies contacted

**House of Representatives  
Senate**

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Keaney, David</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_ Date 8/1/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

**H.CON.RES.95** , Establishing the congressional budget for the United States Government for fiscal year 2003 and 2005 through 2013,

**H.J.RES.2** , Joint Resolution making consolidated appropriations for the fiscal year ending September 30, 2003, for other purposes, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.

**H.R.1559** , Emergency Wartime Supplemental Appropriations Act, 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.

**H.R.2618** , Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry and to prevent funding for the NIH.

**H.R.2673**, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2004., Lobbied to obtain full funding for the FDA.

17. House(s) of Congress and Federal agencies contacted

Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Johnson, Mary-Sumpter	
Keaney, David	
Ryan, John	
Thompson, Richard	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_ Date 8/1/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.2660, Departments of Labor, Health and Human Services, and Education Related Agencies Appropriations Act, 2004, Lobbied to prevent the passage provisions and amendments that are adverse to the industry and to provide funding for the NIH and Ryan White AIDS program and peripheral artery disease.
16	Lobbying Issues	S.1356, Departments of Labor, Health and Human Services, and Education Related Agencies Appropriations Act, 2004, Lobbied to prevent the passage provisions and amendments that are adverse to the industry and to provide funding for the NIH.
16	Lobbying Issues	S.1427, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2004., Lobbied to obtain full funding for FDA.; prevent amendments that would weaken the ability of the FDA to prevent unsafe pharmaceutical products from being imported into the US.
16	Lobbying Issues	S.762, Supplemental Appropriations Act to Support Department of Defense Operations in Iraq for Fiscal Year 2003, Lobbied to prevent the passage of provisions and amendments adverse to the industry.



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CAW (one per page)

16. Specific Lobbying issues

**S.6 , Wastewater Treatment Works Security and Safety Act, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

17. House(s) of Congress and Federal agencies contacted  
**Senate**

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Keaney, David</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_ Date 8/1/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

**H.R.1561 , United States Patent and Trademark Fee Modernization Act of 2003, Lobbied to prevent amendments that would undermine industry intellectual property and other interests.**

**H.R.2344 , Intellectual Property Protection Restoration Act of 2003, Lobbied to prevent amendments that would undermine industry intellectual property and other interests.**

**H.R.2391 , Cooperative Research and Technology Enhancement (CREATE) Act of 2003, Lobbied to prevent amendments that would undermine industry intellectual property and other interests.**

**H.R.247 , Departments of Commerce, Justice, and State, the Judiciary, and Related Agencies Appropriation Act of 2003, Lobbied to prevent amendments that would undermine industry intellectual property and other interests.**

**H.R.2491 , Greater Access to Affordable Pharmaceuticals Act, Lobbied to ensure that any Hatch/Waxman amendments are fair and balanced.**

17. House(s) of Congress and Federal agencies contacted  Check if None  
**House of Representatives**  
**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Carozza, Michael</b>	
<b>Johnson, Mary-Sumpter</b>	
<b>Keaney, David</b>	
<b>Ryan, John</b>	
<b>Thompson, Richard</b>	
<b>Warr, David</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date **8/1/2003**

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.2640 , To provide greater access to affordable pharmaceuticals, and for purposes, Lobbied to prevent the passage of amendments that are adverse to industry.
16	Lobbying Issues	H.R.909 , To amend title 35, United States Code, to direct the Director of the Patent and Trademark Office to adjust fees charged by the Office so that the collected in any fiscal year will equal, to the greatest extent practicable, the amount appropriated to , Lobbied to prevent amendments that would undermine industry intellectual property and other interests.
16	Lobbying Issues	S.1191 , Intellectual Property Protection Restoration Act of 2003, Lobbied to prevent amendments that would undermine industry intellectual property and other interests.
16	Lobbying Issues	S.1225 , Greater Access to Affordable Pharmaceuticals Act, Lobbied to ensure any Hatch/Waxman Act reforms are fair and balanced.
16	Lobbying Issues	S.51 , Generic Pharmaceutical Access and Choice for Consumers Act of 2003: Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	S.54 , Greater Access to Affordable Pharmaceuticals Act of 2003, Lobbied to ensure that any Hatch/Waxman Act reforms are fair and balanced.
16	Lobbying Issues	S.946 , Drug Competition Act of 2003, Lobbied to prevent amendments that undermine industry intellectual property and other interests.



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CSP (one per page)

16. Specific Lobbying issues

**H.R.1197 , Product Safety Notification and Recall Effectiveness Act of 2003, Lobbied to prevent the passage and amendments that are adverse to the industry.**

**H.R.1636 , Consumer Privacy Protection Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

**H.R.1709 , Stop Taking Our Health Privacy (STOHP) Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

**H.R.1766 , National Uniform Privacy Standards Act of 2003, Lobbied to prevent the passage of provisions and amendments that would restrict the industry's ability to utilize clinical trial data that is essential to find new**

**H.R.1931 , Personal Information Privacy Act of 2003, Lobbied to prevent the passage of provisions and amendments that would restrict the industry's ability to utilize clinical trial data that is essential to find new cures.**

17. House(s) of Congress and Federal agencies contacted  Check if None

**House of Representatives**

**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Keaney, David</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date **8/1/2003**

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** \_\_\_\_\_ Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.2196 , Medical Independence, Privacy, and Innovation Act of 2003, Lobb to prevent the passage of provisions and amendments that would restrict the industry's ability to utilize clinical trial data that is essential to find new cures.
16	Lobbying Issues	H.R.2544 , Medical Independence, Privacy, and Innovation Act of 2003, Lobb to prevent the passage of provisions and amendments that would restrict the industry's ability to utilize clinical trial data that is essential to find new cures.
16	Lobbying Issues	H.R.2652 , Internet Pharmacy Consumer Protection Act, Lobbied to prevent passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.663 , Patient Safety and Quality Improvement Act, Lobbied for legislation that would encourage and promote the sharing of information on quality problems and medical errors without the fear of costly and unnecessary litigation.
16	Lobbying Issues	H.R.781 , Privacy Protection Clarification Act, Lobbied to prevent the passage of provisions and amendments that would restrict the industry's ability to utilize clinical trial data that is essential to find new cures.
16	Lobbying Issues	S.1286 , Seniors Safety Act of 2003, Lobbied to prevent the passage of provisions and amendments that would restrict the industry's ability to utilize clinical trial data that is essential to find new cures.
16	Lobbying Issues	S.720 , Patient Safety and Quality Improvement Act, Lobbied for legislation that would encourage and promote the sharing of information on quality problems and medical errors without the fear of costly and unnecessary litigation.
16	Lobbying Issues	S.745 , Privacy Act of 2003, Lobbied to prevent the passage of provisions and amendments that would restrict the industry's ability to utilize clinical trial data that is essential to find new cures.



Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code ECN (one per page)

16. Specific Lobbying issues

**H.R.2427 , Pharmaceutical Market Access Act of 2003, Lobbied to prevent price controls upon the industry.**

17. House(s) of Congress and Federal agencies contacted  
**House of Representatives**

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Carozza, Michael</b>	
<b>Johnson, Mary-Sumpter</b>	
<b>Keaney, David</b>	
<b>Ryan, John</b>	
<b>Thompson, Richard</b>	
<b>Warr, David</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_ Date 8/1/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ENV (one per page)

16. Specific Lobbying issues  
**No activity.**

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date **8/1/2003**

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code FOO (one per page)

16. Specific Lobbying issues

**H.R.1160 , Milk Import Tariff Equity Act, Lobbied to prevent restrictions on the importation of key ingredients for infant formula.**

**S.154 , Emergency Agricultural Disaster Assistance Act of 2003, Lobbied to prevent restrictions on the importation of key ingredients for infant formula.**

**S.40 , Quality Cheese Act of 2003, Lobbied to prevent restrictions on the importation of key ingredients for infant formula.**

**S.560 , Milk Import Tariff Equity Act, Lobbied to prevent restrictions on the importation of key ingredients for infant formula.**

17. House(s) of Congress and Federal agencies contacted  Check if None

**House of Representatives**  
**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Keaney, David</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 8/1/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code FOR (one per page)

16. Specific Lobbying issues

**H.CON.RES.180 , Calling on the President to urge the other members of the Group of Eight (G-8) at the G8 meeting from June 1-3, 2003, in Evian, France, to pledge and contribute a substantial amount of new resources to fight against HIV/AIDS, tuberculosis., Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

**H.R.1298 , United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

**H.R.1857 , Humanitarian Assistance to Combat HIV/AIDS in sub-Saharan Africa and the Caribbean and the Caribbean Security Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

**H.R.1950 , Foreign Relations Authorization Act, Fiscal Years 2004 and 2005, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

**S.250 , Global CARE Act, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

17. House(s) of Congress and Federal agencies contacted

Check if None

**Department of Health & Human Services**

**House of Representatives**

**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Carozza, Michael</b>	
<b>Johnson, Mary-Sumpter</b>	
<b>Thompson, Richard</b>	
<b>Warr, David</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_ Date 8/1/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.2069 , Stop Tuberculosis (TB) Now Act, Lobbied to prevent the passage provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.2470 , Medicines to Eliminate Diseases in Developing States Act, Lobbie prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	S.1009 , United States Emergency Plan for AIDS Relief Act of 2003, Lobbied prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	S.1067 , AIDS Corps Act of 2003, Lobbied to prevent the passage of provisio amendments that are adverse to the industry.
16	Lobbying Issues	S.1161 , Foreign Assistance Authorization Act, fiscal year 2004, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	S.859 , Microbicide Development Act of 2003, Lobbied to prevent the passag provisions and amendments that are adverse to the industry.



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code GOV (one per page)

16. Specific Lobbying issues

**H.R.1389 , Homeland Emergency Response Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

**H.R.2555 , Department of Homeland Security Appropriations Act, 2004, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

**S.15 , Biodefense Improvement and Treatment for America Act, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

**S.22 , Justice Enhancement and Domestic Security Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

17. House(s) of Congress and Federal agencies contacted  Check if None  
**House of Representatives**  
**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Carozza, Michael</b>	
<b>Johnson, Mary-Sumpter</b>	
<b>Keaney, David</b>	
<b>Thompson, Richard</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date **8/1/2003**

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

**H.CON.RES.225** , Expressing the sense of the Congress that the illegal importation of prescription drugs undermines the regulatory protections afforded to United States consumers, and for other purposes, Lobbied the passage of provisions and amendments that are adverse to the industry.

**H.R.1068** , Pancreatic Islet Cell Transplantation Act of 2003, Lobbied to prevent unnecessary restrictions or scientific and clinical research.

**H.R.1120** , Health Care Antitrust Improvements Act of 2003, Lobbied to ensure and foster continued patient quality of care by clarifying the application of the antitrust laws to negotiations between groups of health care professionals and health plans and health care insurance issuers.

**H.R.1158** , Medical Liability Insurance Crisis Response Act of 2003, Lobbied to improve patient access to health services and products and to provide improved medical care by reducing the excessive burden the liability system on the health care delivery system.

17. House(s) of Congress and Federal agencies contacted  Check if None

**Department of Health & Human Services**  
**House of Representatives**  
**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Carozza, Michael</b>	
<b>Johnson, Mary-Sumpter</b>	
<b>Keaney, David</b>	
<b>Ryan, John</b>	
<b>Thompson, Richard</b>	
<b>Warr, David</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 8/1/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.1200 , American Health Security Act of 2003, Lobbied to prevent the pa
16	Lobbying Issues	of provisions that would impose unreasonable price controls on US manufac
16	Lobbying Issues	H.R.1205 , MediKids Health Insurance Act of 2003, Lobbied to ensure great
16	Lobbying Issues	access to pediatric pharmaceutical products for children and for the develop
16	Lobbying Issues	of better padiatric drugs.
16	Lobbying Issues	H.R.1243 , Prescription Drug Benefit Equity Act of 2003, Lobbied to preven
16	Lobbying Issues	passage of provisions that would impose unreasonable price controls on US
16	Lobbying Issues	manufacturers.
16	Lobbying Issues	H.R.1247 , Quality Health Care Coalition Act of 2003, Lobbied to ensure an
16	Lobbying Issues	fooster continued patient safety and quality of care by exempting health care
16	Lobbying Issues	professionals from the Federal antitrust laws in their negotiations with healt
16	Lobbying Issues	plans and health insurance issuers.
16	Lobbying Issues	H.R.1260 , Animal Drug User Fee Act of 2003, Lobbied to ensure the adopti
16	Lobbying Issues	reasonable fees for animal drug applications.
16	Lobbying Issues	H.R.1309 , Veterans Prescription Drug Benefits Act of 2003, Lobbied to prev
16	Lobbying Issues	the passage of provisions that would impose unreasonable price controls on l
16	Lobbying Issues	manufacturers.
16	Lobbying Issues	H.R.15 , National Health Insurance Act, Lobbied to provide a Medicare
16	Lobbying Issues	prescription drug benefit that will enable millions of America's seniors to rec
16	Lobbying Issues	coverage for these products.
16	Lobbying Issues	H.R.1568 , Medicare Rx Now Act of 2003, Lobbied to provide a Medicare
16	Lobbying Issues	prescription drug benefit that will enable millions of America's seniors to rec
16	Lobbying Issues	coverage for these products.
16	Lobbying Issues	H.R.1622 , Quality Cancer Care Preservation Act, Lobbied to provide for gr
16	Lobbying Issues	access to affordable pharmcetuical products to treat cancer.
16	Lobbying Issues	H.R.1694 , Amerca Rx Act of 2003, Lobbied to prevent the passage of provis
16	Lobbying Issues	and amendments that would prevent the general public from being adequate
16	Lobbying Issues	informed about pharmaceutical products.
16	Lobbying Issues	H.R.2021 , Access to Cancer Clinical Trials Act of 2003, Lobbied to provide i
16	Lobbying Issues	greater access to affordable pharmaceutical products to treat cancer.
16	Lobbying Issues	H.R.2068 , Comprehensive Tuberculosis Elimination Act of 2003, Lobbied to
16	Lobbying Issues	provide for greater access to affordable pharmaceutical products to treat
16	Lobbying Issues	Tuberculosis (TB).
16	Lobbying Issues	H.R.2069 , Stop Tuberculosis (TB) Now Act, Lobbied to provide for greater :
16	Lobbying Issues	to affordable pharmaceutical products to treat Tuberculosis (TB).
16	Lobbying Issues	H.R.2122 , Project BioShield Act of 2003, Lobbied to ensure the reasonable a
16	Lobbying Issues	efficient development of counter bioterrorism pharmaceutical products.
16	Lobbying Issues	H.R.2161 , Prescription Value Act, Lobbied to prevent the passage of provisi
16	Lobbying Issues	and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.2196 , Medical Independence, Privacy, and Innovation Act of 2003, Lob
16	Lobbying Issues	to prevent the passage of provisions and amendments that would restrict the
16	Lobbying Issues	reasonable use of clinical data.
16	Lobbying Issues	H.R.2232 , To amend the Federal Food, Drug, and Cosmetic Act relating to t
16	Lobbying Issues	distribution chain of prescription drugs, Lobbied to prevent the passage of
16	Lobbying Issues	provisions and amendments that would increase the flow of imported harmft
16	Lobbying Issues	counterfeit drug products into the USA.
16	Lobbying Issues	H.R.2258 , Hispanic Health Improvement Act of 2003, Lobbied to provide fo
16	Lobbying Issues	programs and activities to improve the health of Hispanic individuals.
16	Lobbying Issues	H.R.234 , Human Cloning Prohibition Act of 2003, Lobbied to prevent unnec
16	Lobbying Issues	restrictions on legitimate scientific and clinical research.
16	Lobbying Issues	H.R.2356 , Prescription Drug Comparative Effectiveness Act of 2003, Lobbie
16	Lobbying Issues	prevent the passage of provisions and amendments that are adverse to the
16	Lobbying Issues	industry.
16	Lobbying Issues	H.R.2391 , Cooperative Research and Technology Enhancement (CREATE)
16	Lobbying Issues	2003, Lobbied to prevent the passage of provisions and amendments that wo
16	Lobbying Issues	unnecessarily restrict the use cooperative research and development agreem



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.2402 , Health Coverage, Affordability, Responsibility, and Equity Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.2427 , Pharmaceutical Market Access Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.2461 , Equal Access to Prescription Drugs for All Seniors Act, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.2497 , Prescription Drug Parity for Americans Act, Lobbied to prevent the passage of provisions that would impose unreasonable price controls on US manufacturers.
16	Lobbying Issues	H.R.2514 , Honor Thy Parents Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.2544 , Medical Independence, Privacy, and Innovation Act of 2003, Lobbied to prevent the passage of amendments and provisions that would restrict the reasonable use of clinical data.
16	Lobbying Issues	H.R.2577 , To require the Comptroller General to conduct a study and submit to Congress a report on price controls of foreign governments on pharmaceuticals. Lobbied to require the Comptroller General to conduct a fair and balanced study on price controls of foreign governments on pharmaceuticals.
16	Lobbying Issues	H.R.2640 , To provide greater access to affordable pharmaceuticals, and for other purposes, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.2652 , Internet Pharmacy Consumer Protection Act, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.354 , North American Prescription Price Equity Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.38 , More Savings, More Choice Prescription Drug Act of 2003, Lobbied to provide a Medicare prescription drug benefit that will enable millions of American seniors to receive coverage for these products.
16	Lobbying Issues	H.R.5 , Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH CARE) Act of 2003, Lobbied to improve patient access to health care services and products to provide improved medical care by reducing the excessive burden the liability system places on the health care delivery system.
16	Lobbying Issues	H.R.534 , Human Cloning Prohibition Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.608 , Pharmaceutical Products Price Equity Act, Lobbied to prevent the passage of provisions that would import foreign price controls on US manufacturers.
16	Lobbying Issues	H.R.616 , Prescription Drug Affordability Act, Lobbied to prevent the passage of provisions that would permit the importation of defective counterfeit foreign products or foreign price controls.
16	Lobbying Issues	H.R.634 , To provide Medicare beneficiaries with access to prescription drug Federal Supply Schedule prices, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.635 , To assure that enrollment in any Medicare prescription drug program is voluntary, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage for these products.
16	Lobbying Issues	H.R.676 , Expanded and Improved Medicare for All Act, Lobbied to provide Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage for these products.
16	Lobbying Issues	H.R.725 , Ephedrine Alkaloid Consumer Protection Act, Lobbied to provide Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage for these products.
16	Lobbying Issues	H.R.780 , Prescription Drug Price Reduction Act, Lobbied to prevent the passage of provisions that would impose unreasonable price controls on US manufacturers.

|

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.810 , Medicare Regulatory and Contracting Reform Act of 2003, Lobbied to provide a Medicare prescription drug benefit that will enable millions of Americans seniors to receive coverage for these products.
16	Lobbying Issues	H.R.828 , Pharmaceutical Fiscal Accountability Act of 2003, Lobbied to prevent the passage of provisions that would impose unreasonable price controls on pharmaceutical manufacturers.
16	Lobbying Issues	H.R.847 , Preserving Access to Safe Affordable Canadian Medicines Act of 2003, Lobbied to prevent the passage of provisions that would permit the importation of defective counterfeit foreign products or foreign price controls.
16	Lobbying Issues	H.R.865 , Smallpox Vaccine Compensation and Safety Act of 2003, Lobbied to ensure a fair and reasonable vaccine compensation program.
16	Lobbying Issues	H.R.896 , Breast Cancer Prescription Drug Fairness Act of 2003, Lobbied to provide for greater access to affordable pharmaceutical products to treat cancer.
16	Lobbying Issues	H.R.936 , Leave No Child Behind Act of 2003, Lobbied to ensure greater access to pediatric pharmaceutical products for children and for the development of new pediatric drugs.
16	Lobbying Issues	S.1009 , United States Emergency Plan for AIDS Relief Act of 2003, Lobbied to increase government assistance to combat the Global AIDS crisis.
16	Lobbying Issues	S.1030 , HealthCARE Act of 2003, Lobbied to expand the number of individuals and families with health insurance coverage and provide greater access to pharmaceutical products.
16	Lobbying Issues	S.11 , Patients First Act of 2003, Lobbied to ensure fair and appropriate access to pharmaceutical products.
16	Lobbying Issues	S.1101 , National Cancer Act of 2003, Lobbied for a comprehensive Federal program relating to early detection of, treatment for, and the prevention of cancer.
16	Lobbying Issues	S.1159 , Hispanic Health Improvement Act of 2003, Lobbied to provide for programs and activities to improve the health of Hispanic individuals.
16	Lobbying Issues	S.1300 , Prescription Drug Consumer Information Act of 2003, Lobbied to prohibit a health plan from contracting with a pharmacy benefit manager (PBM) unless the PBM satisfies certain requirements.
16	Lobbying Issues	S.1369 , A bill to ensure that prescription drug benefits offered to Medicare enrollees in the Federal Employees Health Benefits Program are at least equivalent to the actuarial value of the prescription drug benefits offered to enrollees under the plan generally, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	S.1374 , Better HEALTH Act of 2003, Lobbied to provide health care professionals with immediate relief from increased medical malpractice insurance costs and deal with the root causes of the medical malpractice insurance crisis.
16	Lobbying Issues	S.15 , Biodefense Improvement and Treatment for America Act, Lobbied to protect the industry's intellectual property and to provide patient access to affordable pharmaceutical products.
16	Lobbying Issues	S.245 , Human Cloning Prohibition Act of 2003, Lobbied to prevent unnecessary restrictions on legitimate scientific and clinical research.
16	Lobbying Issues	S.306 , Seniors Health and Independence Preservation Act of 2003, Lobbied to provide Medicare prescription drug benefit proposals that will provide greater affordable access to drug products for America's seniors.
16	Lobbying Issues	S.313 , Animal Drug User Fee Act of 2003, Lobbied to ensure that reasonable fees are imposed for animal drug applications.
16	Lobbying Issues	S.448 , Leave No Child Behind Act of 2003, Lobbied to ensure greater access to pediatric pharmaceutical products for children and for the development of new pediatric drugs.
16	Lobbying Issues	S.465 , Access to Innovation for Medicare Patients Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	S.468 , Senior Nutrition Act of 2003, Lobbied to provide better access to nutritional products for seniors.
16	Lobbying Issues	S.477 , Preserving Prescription Drug Discounts Act, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.

|

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S.51 , Generic Pharmaceutical Access and Choice for Consumers Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	S.518 , Pancreatic Islet Cell Transplantation Act of 2003, Lobbied to prevent unnecessary restrictions on legitimate scientific and clinical research.
16	Lobbying Issues	S.542 , Rx Flexibility for States Act, Lobbied to ensure that states do not impose unreasonable drug rebate agreements in order to make outpatient prescription drugs accessible and affordable for residents of the state who are not otherwise eligible for medical assistance under Medicaid.
16	Lobbying Issues	S.581 , Health Care That Works for All Americans Act of 2003, Lobbied to ensure that there is fair and balanced public debate about how to improve the health care system for Americans.
16	Lobbying Issues	S.607 , HEALTH Act of 2003, Lobbied to reduce the excessive burden the health care system places on health care delivery systems.
16	Lobbying Issues	S.650 , Pediatric Research Equity Act of 2003, Lobbied to ensure greater access to pediatric pharmaceutical products for children and for the development of new pediatric drugs.
16	Lobbying Issues	S.666 , Biological, Chemical, and Radiological Weapons Countermeasures Research Act, Lobbied to ensure the reasonable and efficient development of counter bioterrorism pharmaceutical products.
16	Lobbying Issues	S.7 , Prescription Drug Benefit and Cost Containment Act of 2003, Lobbied to provide a Medicare prescription drug benefit that will enable millions of Americans to receive coverage for these products.
16	Lobbying Issues	S.722 , Dietary Supplement Safety Act of 2003, Lobbied to ensure that health claims for dietary supplements are based on sound scientific data.
16	Lobbying Issues	S.732 , Health Care Safety Net Oversight Act of 2003, Lobbied to ensure that an independent and nonpartisan commission created by this bill to assess the health care needs of the uninsured and to monitor the financial stability of the National health care safety net be balanced and fair.
16	Lobbying Issues	S.874 , Sickle Cell Treatment Act of 2003, Lobbied to obtain the best bill for patient.
16	Lobbying Issues	S.906 , Health Care Access for Small Businesses Act of 2003, Lobbied to provide greater access to affordable pharmaceutical products.
16	Lobbying Issues	S.946 , Drug Competition Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	S.948 , Drug Company Gift Disclosure Act, Lobbied to ensure that the bill's requirements that prescription drug manufacturers, packers, and distributors disclose certain gifts provided in connection with detailing, promotional, or other marketing activities be fair and less burdensome.
16	Lobbying Issues	S.951 , Older Americans Prescription Drug Tax Relief Act, Lobbied for provisions that would provide seniors with greater access to affordable pharmaceutical products.

|

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code INS (one per page)

16. Specific Lobbying issues

**H.R.1228 , Patient and Physician Safety and Protection Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

**H.R.1733 , Senior Bill of Rights Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

**H.R.597 , Patient Protection Act, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

**S.952 , Patient and Physician Safety and Protection Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.**

17. House(s) of Congress and Federal agencies contacted  Check if None

**House of Representatives**  
**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Carozza, Michael</b>	
<b>Keaney, David</b>	
<b>Ryan, John</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 8/1/2003

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code LAW (one per page)

16. Specific Lobbying issues  
**No activity.**

0  
0  
0  
0  
5  
2  
8  
3  
7

17. House(s) of Congress and Federal agencies contacted

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_ Date 8/1/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code LBR (one per page)

16. Specific Lobbying issues  
**No activity.**

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date **8/1/2003**

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** \_\_\_\_\_ Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

- 15. General issue area code MED (one per page)
- 16. Specific Lobbying issues  
**No activity.**

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date **8/1/2003**

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

**H.R.1 , Medicare Prescription Drug and Modernization Act of 2003, Lobbied to ensure the future financial of the federal Medicare program and consumer choice.**

**H.R.1045 , Medicare Outpatient Prescription Drug Coverage Act of 2003, Lobbied to prevent the passage of and amendments that are adverse to the industry.**

**H.R.1199 , Medicare Rx Drug Benefit and Discount Act of 2003, Lobbied to prevent the passage of provision impose unreasonable price controls on US manufacturers.**

**H.R.1400 , Prescription Drug Fairness for Seniors Act of 2003, Lobbied to provide a Medicare prescription that will enable millions of America's seniors to receive coverage of these products.**

**H.R.2473 , Medicare Prescription Drug and Modernization Act of 2003, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage of these products.**

17. House(s) of Congress and Federal agencies contacted

Check if None

**Department of Health & Human Services  
House of Representatives  
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Carozza, Michael</b>	
<b>Johnson, Mary-Sumpter</b>	
<b>Keaney, David</b>	
<b>Ryan, John</b>	
<b>Thompson, Richard</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_ Date 8/1/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.2498 , Medicare Extension of Drugs to Seniors (MEDS) Act of 2003, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage of these products.
16	Lobbying Issues	H.R.2578 , Medicare for the 21st Century Act, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage of these products.
16	Lobbying Issues	H.R.26 , Medicare Payment Restoration and Benefits Improvement Act of 2003, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage of these products.
16	Lobbying Issues	H.R.2606 , To amend title XVIII of the Social Security Act to provide prescription drug coverage under the Medicare Program, to make improvements in Medicare payment for rural providers, and for other purposes, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage of these products.
16	Lobbying Issues	H.R.2631 , To provide that the actuarial value of the prescription drug benefit offered to Medicare eligible enrollees by a plan under the Federal employees health benefits program shall be at least equal to the actuarial value of the prescription drug benefits offered, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage of these products.
16	Lobbying Issues	H.R.513 , Medicare Rx Drug Discount Act of 2003, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage of these products.
16	Lobbying Issues	H.R.960 , Seniors Health and Independence Preservation Act of 2003, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage of these products.
16	Lobbying Issues	H.R.980 , Access to Innovation for Medicare Patients Act of 2003, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage of these products.
16	Lobbying Issues	S.1 , Prescription Drug and Medicare Improvement Act of 2003, Lobbied to ensure the future financial viability of the federal Medicare program and consumer choice.
16	Lobbying Issues	S.10 , Health Care Coverage Expansion and Quality Improvement Act of 2003, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage of these products.
16	Lobbying Issues	S.1332 , Medicare Educational Regulatory Reform, and Contracting Improvement Act of 2003, Lobbied for fair regulatory relief, appeals process reforms, contracting flexibility, and education improvements under the Medicare program.
16	Lobbying Issues	S.778 , Medicare Rx Drug Discount and Security Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	S.891 , Prescription Drug Equity for Seniors Act of 2003, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage of these products.
16	Lobbying Issues	S.892 , Prescription Drug Fairness for Seniors Act of 2003, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage of these products.
16	Lobbying Issues	Lobbied for changes in Medicare regulations regarding payment for prescription drugs and against functional equivalence.



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific Lobbying issues  
**No activity.**

17. House(s) of Congress and Federal agencies contacted

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_ Date 8/1/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

**H.R.1612 , To make permanent the tax benefits enacted by the Economic Growth and Tax Relief Reconciliation Act of 2001, Lobbied to safeguard and enhance the economic well being of the Company.**

**H.R.1769 , Job Protection Act of 2003, Lobbied to seek fair replacement for the current extra territorial income tax (ETI).**

**H.R.2 , Jobs and Growth Tax Act of 2003, Lobbied to safeguard and enhance the economic well being of the Company.**

**H.R.210 , To amend the Internal Revenue Code of 1986 to accelerate the individual income tax rate cuts made by the Economic Growth and Tax Relief Reconciliation Act of 2001 and to make permanent all tax cuts made by the Act. Lobbied to safeguard and enhance the economic well being of the Company.**

**H.R.407 , To repeal the sunset of the provisions of the Economic Growth and Tax Relief Reconciliation Act of 2001. Lobbied to safeguard and enhance the economic well being of the Company.**

**H.R.463 , Investment in America Act of 2003, Lobbied to make permanent the R&D tax credit.**

17. House(s) of Congress and Federal agencies contacted  Check if None

House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Johnson, Mary-Sumpter	
Keaney, David	
Ryan, John	
Thompson, Richard	
Warr, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date **8/1/2003**

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Page

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.767 , Homeland Investment Act of 2003, Lobbied to reduce the taxation overseas corporate earnings.
16	Lobbying Issues	S.2 , Jobs and Growth Tax Act of 2003, Lobbied to promote a favorable corporate tax structure for the Company.
16	Lobbying Issues	S.476 , CARE Act of 2003, Lobbied to make permanent the R&D tax credit.
16	Lobbying Issues	S.596 , Invest in the U.S.A. Act of 2003, Lobbied to seek fair replacement for current extra territorial income regime (ETI).
16	Lobbying Issues	S.664 , Investment in America Act of 2003, Lobbied to make permanent the tax credit.
16	Lobbying Issues	S.936 , Government Settlement Transparency Act of 2003, Lobbied to prevent obstacles to the reasonable settlement of disputes with the government.



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TEC (one per page)

16. Specific Lobbying issues  
**No activity.**

17. House(s) of Congress and Federal agencies contacted

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_ Date 8/1/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TOR (one per page)

16. Specific Lobbying issues

**H.R.1115 , Class Action Fairness Act of 2003, Lobbied to ensure passage of legislation to reduce abuses in the system.**

**H.R.1116 , Medical Malpractice Insurance and Litigation Reform Act, Lobbied to improve the legal process to liability issues.**

**H.R.1124 , Medical Malpractice Reform Act of 2003, Lobbied to improve the legal process with respect to li:**

**H.R.1219 , Medical Malpractice and Insurance Reform Act of 2003, Lobbied to improve the legal process wi liability issues.**

**H.R.5 , Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2003, Lobbied to ensure t damages will not be available in cases involving FDA approved products unless the manufacturer failed to c specific requirement of the FD&C Act.**

**S.274 , Class Action Fairness Act of 2003, Lobbied to ensure passage of legislation to reduce abuses in the leg**

17. House(s) of Congress and Federal agencies contacted

Check if None

**House of Representatives**

**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Keaney, David</b>	
<b>Ryan, John</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_ Date 8/1/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs Pag

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S.11 , Patients First Act of 2003, Lobbied to ensure that punitive damages will be available in cases involving FDA approved products unless the manufacturer failed to comply with a specific requirement of the FD&C Act.
16	Lobbying Issues	S.507 , Efficient Energy through Certified Technologies (EFFECT) Act of 2003, Lobbied to ensure that punitive damages will not be available in cases involving FDA approved products unless the manufacturer failed to comply with a specific requirement of the FD&C Act.
16	Lobbying Issues	S.607 , HEALTH Act of 2003, Lobbied to ensure that punitive damages will be available in cases involving FDA approved products unless the manufacturer failed to comply with a specific requirement of the FD&C Act.



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues  
**S.1234 , Federal Trade Commission Reauthorization Act of 2003, Lobbied to prevent the passage of provisions amendments that are adverse to the industry.**  
**Discussed European reclassification of ostomy products.**

17. House(s) of Congress and Federal agencies contacted  Check if None  
**Department of Commerce**  
**Department of Health & Human Services**  
**House of Representatives**  
**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Carozza, Michael</b>	
<b>Johnson, Mary-Sumpter</b>	
<b>Keaney, David</b>	
<b>Ryan, John</b>	
<b>Thompson, Richard</b>	
<b>Warr, David</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date **8/1/2003**

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Page

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

00000252849

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

21. Client new principal place of business (if different from line 20)

City State/Zip (or Country)

22. New general description of client's business or activities

**Pharmaceutical Research & Development**

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

**ISSUE UPDATE**

24. General lobbying issues previously reported that **no longer** pertain

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)


26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrant or affiliated organization

Signature  Date 8/1/2003

Printed Name and Title Richard Thompson - Senior Vice President, Policy & Government Affairs Pag